At some point, COVID will come to an end (or, as some experts point out, will become endemic and life will stabilize). From a chemical supply chain perspective, however, what does a post-COVID world look like? Read on for five ways chemical supply chains will likely evolve.
Categories for COVID-19/Coronavirus
SOCMA Blog: While we are not at the finish line on OSHA’s Emergency Temporary Standard (ETS) on COVID-19 Vaccination and Testing, the Supreme Court dealt a strong blow against it on Thursday, stating in the decision that the Court believes legal opposition to the ETS is “likely to prevail.”
The Supreme Court reinstituted the stay of OSHA’s COVID–19 Vaccination and Testing Emergency Temporary Standard (ETS). OSHA may not enforce the ETS until and unless there is a decision on the merits of the case from the U.S. Court of Appeals for the Sixth Circuit in favor of OSHA, a decision that will be appealed to the Supreme Court.
SOCMA hosted a roundtable on August 17 to address operational best practices and legal challenges around vaccine mandates, as the Delta Variant continues to change the trajectory of recovery from COVID-19.
Lonza and Moderna Announce Further Collaboration For Drug Substance Manufacturing of COVID-19 Vaccine Moderna in the Netherlands
Lonza today announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The expanded collaboration will further extend the manufacture of the drug substance for the COVID-19 Vaccine Moderna and provides for the installation of a new manufacturing line for drug substance production at Lonza’s Geleen (NL) site.
Lonza and Moderna Enter New Agreement to Double Drug Substance Production for COVID-19 Vaccine in Visp
Lonza today announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to manufacture the drug substance for the COVID-19 Vaccine Moderna.
As SOCMA continues to keep a pulse on the specialty and fine chemical industry, we understand that companies across the industry are grappling with how to encourage employee inoculations now that there’s increased availability of COVID-19 vaccines. We’ve spoken with leaders from Texas to Rhode Island and everywhere in between about how they are handling the vaccination within their companies, and here are a few takeaways you can consider when implementing your own plans.
With chemical safety, security and trade as crucial focal points for the specialty chemical value chain, the Society of Chemical Manufacturers & Affiliates (SOCMA) looks forward to continuing a robust dialogue and working with newly appointed Department of Homeland Security (DHS) Secretary Alejandro Mayorkas and Commerce Secretary Gina Raimondo on these key industry issues.
SOCMA has identified two EOs that will intersect with the work and activities of its Environmental, Health and Safety committee. Alongside our members, we are prepared to further our advocacy efforts through each agency's review and decision process.
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza today announced that the companies have entered into an agreement for the development of CAP-1002, Capricor's leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from COVID-19.